Qiagen (QGEN) Stock Forecast & Price Target
$10.38B
Market Cap
25.83
P/E
20.66
Forward P/E
50
Score
QGEN price $50.38 +0.04 +0.09%
Stocklytics score rationale: value 34, quality 77, growth 40.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 1337991000 | 1417536000 | 1501848000 | 1526424000 | 1870346000 | 2251657000 | 2141518000 | 1965311000 | 1978214000 | 2089998999 |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary…
Consensus Hold from 30 analysts. Average price target $44.01, -12.6% versus the current price. Low $38.60. High $52.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $44.01 for Qiagen (QGEN), 12.6% below the current price of $50.38. Of 30 analysts covering the stock, 13 rate it Buy or Strong Buy, 17 Hold, and 0 Sell or Strong Sell, giving a consensus of Hold.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $38.60 |
|---|---|
| Average | $44.01 |
| High | $52.00 |
The average is 12.6% below the current price of $50.38.
Of 30 analysts, 13 rate Qiagen Buy or Strong Buy, 17 Hold, and 0 Sell or Strong Sell. The consensus label is Hold. That split is not a recommendation.
Analyst averages on file: 2026, EPS $2.44, revenue $2.14 billion. 2027, EPS $2.62, revenue $2.24 billion.
The Stocklytics Score for QGEN is 50 out of 100. It averages value, quality, and growth against a large-cap US universe. It is not a price target and not a buy or sell rating. Fair value is a separate estimate on the fair value tab.
$44.01 average, with a published range of $38.60 to $52.00.
The consensus is Hold from 30 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is $2.44. The average revenue estimate is $2.14 billion.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: Qiagen · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$10.38B
Market Cap
25.83
P/E
20.66
Forward P/E
50
Score